Pfizer and Miles: a contract worth nearly $ 10 billion

The world's leading pharmaceutical group, Pfizer, is in negotiations to merge its non-patented drug division with the pharmaceutical group Mylan, which will lead to the formation of a giant in the field of cheap medicines in the world, reported the Wall Street Journal. The deal, which will generate about $ 12 billion in revenue for Faiser, is expected to be announced Monday, the source said.
The paper says that "Mylan" shareholders, whose market value is currently about $ 10 billion, will receive 40% of the shares of the new entity, with "Pfizer" shareholders representing 60% of the remaining shares. The deal is expected to come at a time when both companies are facing a significant drop in sales, having lost the protection of their patented products and facing fierce competition over the prices of the products on the market.